LABP vs. ACHL, AWH, SNSE, GOSS, ADVM, ANL, NATR, ADCT, ATAI, and ME
Should you be buying Landos Biopharma stock or one of its competitors? The main competitors of Landos Biopharma include Achilles Therapeutics (ACHL), Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), Gossamer Bio (GOSS), Adverum Biotechnologies (ADVM), Adlai Nortye (ANL), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Atai Life Sciences (ATAI), and 23andMe (ME). These companies are all part of the "medical" sector.
Landos Biopharma (NASDAQ:LABP) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
In the previous week, Achilles Therapeutics had 2 more articles in the media than Landos Biopharma. MarketBeat recorded 3 mentions for Achilles Therapeutics and 1 mentions for Landos Biopharma. Landos Biopharma's average media sentiment score of 1.87 beat Achilles Therapeutics' score of 1.29 indicating that Landos Biopharma is being referred to more favorably in the media.
Landos Biopharma received 13 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 62.50% of users gave Landos Biopharma an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Landos Biopharma has higher revenue and earnings than Achilles Therapeutics. Landos Biopharma is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Landos Biopharma has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
49.1% of Landos Biopharma shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 1.3% of Landos Biopharma shares are held by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Achilles Therapeutics' return on equity of -42.95% beat Landos Biopharma's return on equity.
Landos Biopharma currently has a consensus price target of $20.42, indicating a potential downside of 10.95%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 334.78%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Landos Biopharma.
Summary
Achilles Therapeutics beats Landos Biopharma on 10 of the 15 factors compared between the two stocks.
Get Landos Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landos Biopharma Competitors List
Related Companies and Tools
